Delcath Systems Inc
NASDAQ:DCTH
Gross Margin
Delcath Systems Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Delcath Systems Inc
NASDAQ:DCTH
|
396.7m USD |
83%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
224.3B USD |
56%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.1B USD |
67%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
150.7B USD |
69%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.8B USD |
64%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
107.8B USD |
66%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.9B EUR |
38%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.3B USD |
45%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.5B USD |
79%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
35.4B USD |
61%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
257.8B CNY |
64%
|
Delcath Systems Inc
Glance View
Delcath Systems, Inc. is an oncology company, which focuses on the treatment of primary and metastatic liver cancers. The company is headquartered in New York City, New York and currently employs 45 full-time employees. The company went IPO on 2000-10-19. The firm's lead product candidate, the HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) is a drug/device combination product. HEPZATO KIT is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. In Europe, its commercial product is a medical device having the same device components as the HEZPATO KIT but without the melphalan hydrochloride, is designated as a Class III medical device, and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it is being used at various medical centers to treat a range of cancers of the liver. In the United States, HEPZATO KIT is considered a combination drug and device product. The firm's product administers concentrated regional chemotherapy to the liver.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Delcath Systems Inc's most recent financial statements, the company has Gross Margin of 83.4%.
You don't have any saved screeners yet